Time filter

Source Type

Patent
Hong Kong Baptist University and Shanghai University of Traditional Chinese Medicine | Date: 2015-05-01

The present invention provides composition for treating cancer comprising polyprenylated acylphloroglucinol (PPAP) compound. The present invention also provides a composition comprising Guttiferone K for treating esophageal cancer and liver cancer. The present invention further provides a method of using said compound for inhibiting cancer metastasis.


Patent
Shanghai University of Traditional Chinese Medicine and Hong Kong Baptist University | Date: 2014-01-10

The present invention discloses a novel composition with anti-viral effects comprises extracts from Anemarrhena asphodeloides. Method of preparing said extract is also disclosed.


Patent
Hong Kong Baptist University and Shanghai University of Traditional Chinese Medicine | Date: 2015-08-12

A compound of formula (I) or a pharmaceutically acceptable salt, hydrate or prodrug thereof for inhibiting Syk activity,


Patent
Hong Kong Baptist University and Shanghai University of Traditional Chinese Medicine | Date: 2016-04-15

The present invention provides compound extracted from Garcinia species and the use of said compound in preventing and treating cancer.


Qi Y.,Shanghai University of Traditional Chinese Medicine
Molecular & cellular proteomics : MCP | Year: 2012

The incidence of precocious puberty (PP, the appearance of signs of pubertal development at an abnormally early age), is rapidly rising, concurrent with changes of diet, lifestyles, and social environment. The current diagnostic methods are based on a hormone (gonadotropin-releasing hormone) stimulation test, which is costly, time-consuming, and uncomfortable for patients. The lack of molecular biomarkers to support simple laboratory tests, such as a blood or urine test, has been a long standing bottleneck in the clinical diagnosis and evaluation of PP. Here we report a metabolomic study using an ultra performance liquid chromatography-quadrupole time of flight mass spectrometry and gas chromatography-time of flight mass spectrometry. Urine metabolites from 163 individuals were profiled, and the metabolic alterations were analyzed after treatment of central precocious puberty (CPP) with triptorelin depot. A panel of biomarkers selected from >70 differentially expressed urinary metabolites by receiver operating characteristic and logistic regression analysis provided excellent predictive power with high sensitivity and specificity for PP. The altered metabolic profile of the PP patients was characterized by three major perturbed metabolic pathways: catecholamine, serotonin metabolism, and tricarboxylic acid cycle, presumably resulting from activation of the sympathetic nervous system and the hypothalamic-pituitary-gonadal axis. Treatment with triptorelin depot was able to normalize these three altered pathways. Additionally, significant changes in the urine levels of 4-hydroxyphenylacetic acid, 5-hydroxyindoleacetic acid, indoleacetic acid, 5-hydroxytryptophan, and 5-hydroxykynurenamine in the CPP group suggest that the development of CPP condition may involve an alteration in symbiotic gut microbial composition.


BACKGROUND: Androgen receptor (AR) signalling contributes to male predominance in hepatocellular carcinoma (HCC), which is more pronounced in HBV-endemic areas. Cell cycle-related kinase (CCRK) is essential for AR-induced hepatocarcinogenesis but its molecular function in HBV-associated HCC remains obscure.OBJECTIVE: To determine the molecular function of CCRK in HBV-associated HCC.DESIGN: Transcriptional regulation was assessed by chromatin immunoprecipitation, promoter mutation and luciferase reporter assays. Hepatocellular proliferation and tumourigenesis were examined by colony formation, soft agar assays and using HBV X protein (HBx) transgenic mice with low-dose exposure to diethylnitrosamine. Protein expressions were examined in clinical samples and correlated with patient survival by log-rank Mantel-Cox test.RESULTS: Overexpression of CCRK, but not its kinase-defective mutant, activated β-catenin/T cell factor signalling through phosphorylation of glycogen synthase kinase-3β (GSK-3β) at Ser9, led to upregulation of AR transcriptional activity and, subsequently, expression of HBx. The viral transactivator in turn induced CCRK expression through enhanced AR signalling, thus forming a positive regulatory loop. RNA interference silencing of CCRK, which suppressed the CCRK/GSK-3β/β-catenin/AR regulatory loop, significantly suppressed HBx-induced hepatocellular proliferation (p=0.001) and transformation (p<0.001) and remarkably reduced >80% diethylnitrosamine-mediated hepatocarcinogenesis in HBx transgenic mice. Finally, patients with HBV-associated HCC with concordant overexpression of CCRK, GSK-3β phosphorylation at Ser9, active dephosphorylated β-catenin and AR phosphorylation at Ser81 had poorer overall (HR=31.26, p<0.0001) and disease-free (HR=3.60, p<0.01) survival rates.CONCLUSIONS: Our findings highlight the critical role of CCRK in a self-reinforcing circuitry that regulates HBV-associated hepatocarcinogenesis. Further characterisation of this intricate viral-host signalling may provide new prognostic biomarkers and therapeutic targets for HCC treatment. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.


Patent
Shanghai University of Traditional Chinese Medicine | Date: 2014-02-13

A traditional Chinese medicine compound antitumor nano preparation, comprising the following components by weight percentage: 28%-32% of solid lipid nanoparticles containing volatile oil of frankincense and myrrh, 61%-65% of nano realgar carrying microcapsule, 0.8%-1.3% of bezoar micro-powder and 4%-6% of musk micro-powder. Use of the above traditional Chinese medicine compound antitumor nano preparation for preparing antitumor drugs. The traditional Chinese medicine compound antitumor nano preparation of the present invention can remarkably improve bioavailability of every component in the traditional Chinese medicine compound; at the same time, it can achieve better curative effect with reduced dosage.


Patent
Shanghai University of Traditional Chinese Medicine | Date: 2014-01-09

A method for preparing a platelet aggregation inhibitor, a blood coagulation inhibitor, and a pharmaceutical composition or a food for preventing or treating thrombotic diseases, includes applying notoginsenoside Fc.


Patent
Shanghai University of Traditional Chinese Medicine | Date: 2014-04-15

The present invention discloses a PPAR / dual agonist and its application. The PPAR / dual agonist comprises an effective amount of the compounds represented by formula I or/and its pharmaceutically acceptable derivative. Wherein. R_(1 )is selected from alkoxyl or ester group; R_(2 )is selected from hydroxyl or ester group. The PPAR / dual agonist according to the present invention can be used for preparing drugs and functional foods for preventing or/and treating metabolic syndrome, especially glucose or/and lipid disorders, with extensive and bright prospects of application.


Patent
Shanghai University of Traditional Chinese Medicine | Date: 2015-03-11

A traditional Chinese medicine compound antitumor nano preparation, comprising the following components by weight percentage: 28%-32% of solid lipid nanoparticles containing volatile oil of frankincense and myrrh, 61%-65% of nano realgar carrying microcapsule, 0.8%-1.3% of bezoar micro-powder and 4%-6% of musk micro-powder. Use of the above traditional Chinese medicine compound antitumor nano preparation for preparing antitumor drugs. The traditional Chinese medicine compound antitumor nano preparation of the present invention can remarkably improve bioavailability of every component in the traditional Chinese medicine compound; at the same time, it can achieve better curative effect with reduced dosage.

Loading Shanghai University of Traditional Chinese Medicine collaborators
Loading Shanghai University of Traditional Chinese Medicine collaborators